KYTX vs. RKLB
KYTX (Kyverna Therapeutics, Inc) and RKLB (Rocket Lab USA, Inc.) are both stocks. KYTX operates in Biotechnology (Healthcare), while RKLB operates in Aerospace & Defense (Industrials). Over the past year, KYTX returned 180.29% vs 329.27% for RKLB. At a 0.22 correlation, their price movements are largely independent.
Performance
KYTX vs. RKLB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KYTX achieves a -16.81% return, which is significantly lower than RKLB's 64.42% return.
KYTX
- 1D
- -1.01%
- 1M
- -13.11%
- YTD
- -16.81%
- 6M
- 8.91%
- 1Y
- 180.29%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
RKLB
- 1D
- -6.99%
- 1M
- 42.82%
- YTD
- 64.42%
- 6M
- 156.48%
- 1Y
- 329.27%
- 3Y*
- 186.06%
- 5Y*
- —
- 10Y*
- —
KYTX vs. RKLB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
KYTX Kyverna Therapeutics, Inc | -16.81% | 151.34% | -87.53% |
RKLB Rocket Lab USA, Inc. | 64.42% | 173.89% | 492.33% |
Correlation
The correlation between KYTX and RKLB is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Feb 9, 2024 | 0.22 |
Fundamentals
KYTX:
$472.60M
RKLB:
$69.44B
KYTX:
-$3.22
RKLB:
-$0.33
KYTX:
2.42
RKLB:
30.67
KYTX:
$0.00
RKLB:
$679.58M
KYTX:
-$1.30M
RKLB:
$248.43M
KYTX:
-$158.20M
RKLB:
-$177.36M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KYTX vs. RKLB — Risk / Return Rank
KYTX
RKLB
KYTX vs. RKLB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kyverna Therapeutics, Inc (KYTX) and Rocket Lab USA, Inc. (RKLB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KYTX | RKLB | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.69 | 3.61 | -1.92 |
Sortino ratioReturn per unit of downside risk | 2.42 | 3.37 | -0.95 |
Omega ratioGain probability vs. loss probability | 1.30 | 1.41 | -0.11 |
Calmar ratioReturn relative to maximum drawdown | 5.02 | 7.71 | -2.69 |
Martin ratioReturn relative to average drawdown | 10.28 | 18.10 | -7.82 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KYTX | RKLB | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.69 | 3.61 | -1.92 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.45 | 0.76 | -1.21 |
Drawdowns
KYTX vs. RKLB - Drawdown Comparison
The maximum KYTX drawdown since its inception was -93.92%, which is greater than RKLB's maximum drawdown of -82.96%. Use the drawdown chart below to compare losses from any high point for KYTX and RKLB.
Loading charts...
Drawdown Indicators
| KYTX | RKLB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.92% | -82.96% | -10.96% |
Max Drawdown (1Y)Largest decline over 1 year | -36.14% | -43.01% | +6.87% |
Max Drawdown (3Y)Largest decline over 3 years | — | -55.49% | — |
Current DrawdownCurrent decline from peak | -74.02% | -23.65% | -50.37% |
Average DrawdownAverage peak-to-trough decline | -73.18% | -51.47% | -21.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.61% | 18.29% | -0.68% |
Volatility
KYTX vs. RKLB - Volatility Comparison
The current volatility for Kyverna Therapeutics, Inc (KYTX) is 22.01%, while Rocket Lab USA, Inc. (RKLB) has a volatility of 42.00%. This indicates that KYTX experiences smaller price fluctuations and is considered to be less risky than RKLB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KYTX | RKLB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.01% | 42.00% | -19.99% |
Volatility (6M)Calculated over the trailing 6-month period | 74.25% | 72.36% | +1.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 107.69% | 92.02% | +15.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 99.25% | 81.45% | +17.80% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 99.25% | 81.45% | +17.80% |
Dividends
KYTX vs. RKLB - Dividend Comparison
Neither KYTX nor RKLB has paid dividends to shareholders.
Financials
KYTX vs. RKLB - Financials Comparison
This section allows you to compare key financial metrics between Kyverna Therapeutics, Inc and Rocket Lab USA, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
KYTX and RKLB have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RKLB has higher volatility (42.00%) compared to KYTX (22.01%). In terms of maximum drawdown, KYTX dropped -93.92% vs RKLB's -82.96%.
RKLB currently has the higher Sharpe Ratio (3.61 vs 1.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KYTX and RKLB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer